The US Patent and Trademark Office (USPTO) has granted US patent 9,050,358 to Agile Therapeutics, Inc's lead product candidate Twirla (ethinyl estradiol and levonorgestrel transdermal system (AG200-15), currently in phase 3 development.
The newly-issued patent includes claims directed to the peripheral adhesive system used in the Twirla. The patent includes claims that relate to the enhanced adhesion characteristics of the Twirla patch combined with its low rates of skin irritation.
Agile plans to submit information regarding this patent to the FDA for inclusion in the FDA's Orange Book if the company's New Drug Application for Twirla is approved.
The company has multiple additional patents and applications on file, all relating to further advances in Skinfusion transdermal delivery system.
Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products.